Genelux Common Net Worth
Genelux Common Net Worth Breakdown | GNLX |
Genelux Common Net Worth Analysis
Genelux Common's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Genelux Common's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Genelux Common's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Genelux Common's net worth analysis. One common approach is to calculate Genelux Common's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Genelux Common's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Genelux Common's net worth. This approach calculates the present value of Genelux Common's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Genelux Common's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Genelux Common's net worth. This involves comparing Genelux Common's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Genelux Common's net worth relative to its peers.
Enterprise Value |
|
To determine if Genelux Common is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Genelux Common's net worth research are outlined below:
Genelux Common is way too risky over 90 days horizon | |
Genelux Common appears to be risky and price may revert if volatility continues | |
The company reported the previous year's revenue of 170 K. Net Loss for the year was (28.3 M) with profit before overhead, payroll, taxes, and interest of 11.07 M. | |
Genelux Common generates negative cash flow from operations | |
About 16.0% of the company shares are held by company insiders | |
Latest headline from finance.yahoo.com: Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors |
Genelux Common uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Genelux Common. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Genelux Common's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
13th of February 2024 Upcoming Quarterly Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
13th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Genelux Common Target Price Consensus
Genelux target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Genelux Common's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
5 | Strong Buy |
Most Genelux analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Genelux stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Genelux Common, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationGenelux Common Target Price Projection
Genelux Common's current and average target prices are 2.69 and 34.33, respectively. The current price of Genelux Common is the price at which Genelux Common is currently trading. On the other hand, Genelux Common's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Genelux Common Market Quote on 2nd of December 2024
Target Price
Analyst Consensus On Genelux Common Target Price
Follow Genelux Common's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 92.91 M.Market Cap |
|
Project Genelux Common's profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.01) | (1.07) | |
Return On Capital Employed | (1.13) | (1.08) | |
Return On Assets | (1.01) | (1.07) | |
Return On Equity | (1.45) | (1.38) |
When accessing Genelux Common's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Genelux Common's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Genelux Common's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Genelux Common's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Genelux Common. Check Genelux Common's Beneish M Score to see the likelihood of Genelux Common's management manipulating its earnings.
Evaluate Genelux Common's management efficiency
Genelux Common has return on total asset (ROA) of (0.4461) % which means that it has lost $0.4461 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8857) %, meaning that it created substantial loss on money invested by shareholders. Genelux Common's management efficiency ratios could be used to measure how well Genelux Common manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.07 in 2024. Return On Capital Employed is likely to rise to -1.08 in 2024. At this time, Genelux Common's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 25.4 M in 2024, whereas Net Tangible Assets are likely to drop (31.3 M) in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.80 | 0.84 | |
Tangible Book Value Per Share | 0.80 | 0.84 | |
Enterprise Value Over EBITDA | (12.68) | (13.31) | |
Price Book Value Ratio | 17.58 | 18.45 | |
Enterprise Value Multiple | (12.68) | (13.31) | |
Price Fair Value | 17.58 | 18.45 | |
Enterprise Value | 335.4 M | 352.1 M |
The decision-making processes within Genelux Common are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 7.6 K | Revenue 8 K | Quarterly Revenue Growth (0.95) | Return On Equity (0.89) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Genelux Common insiders, such as employees or executives, is commonly permitted as long as it does not rely on Genelux Common's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Genelux Common insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Genelux Common Corporate Filings
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 25th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 22nd of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
Genelux Common Earnings Estimation Breakdown
The calculation of Genelux Common's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Genelux Common is estimated to be -0.22125 with the future projection ranging from a low of -0.23 to a high of -0.2125. Please be aware that this consensus of annual earnings estimates for Genelux Common is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.23 Lowest | Expected EPS | -0.21 Highest |
Genelux Common Earnings Projection Consensus
Suppose the current estimates of Genelux Common's value are higher than the current market price of the Genelux Common stock. In this case, investors may conclude that Genelux Common is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Genelux Common's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
5 | 87.41% | -0.19 | -0.22125 | -0.94 |
Genelux Common Earnings per Share Projection vs Actual
Actual Earning per Share of Genelux Common refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Genelux Common predict the company's earnings will be in the future. The higher the earnings per share of Genelux Common, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Genelux Common Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Genelux Common, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Genelux Common should always be considered in relation to other companies to make a more educated investment decision.Genelux Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Genelux Common's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2024-11-15 | 2024-09-30 | -0.19 | -0.19 | 0.0 | 0 | ||
2024-08-15 | 2024-06-30 | -0.2075 | -0.22 | -0.0125 | 6 | ||
2024-05-09 | 2024-03-31 | -0.23 | -0.29 | -0.06 | 26 | ||
2024-03-29 | 2023-12-31 | -0.19 | -0.25 | -0.06 | 31 | ||
2023-11-14 | 2023-09-30 | -0.18 | -0.2 | -0.02 | 11 | ||
2023-08-14 | 2023-06-30 | -0.15 | -0.23 | -0.08 | 53 | ||
2023-05-15 | 2023-03-31 | -0.16 | -0.53 | -0.37 | 231 | ||
2023-03-29 | 2022-12-31 | 0 | -0.12 | -0.12 | 0 | ||
2022-09-19 | 2022-06-30 | 0 | -0.12 | -0.12 | 0 | ||
2022-06-24 | 2022-03-31 | 0 | -0.16 | -0.16 | 0 |
Genelux Common Corporate Management
Caroline Jewett | VP Quality | Profile | |
Ralph BSc | Head Affairs | Profile | |
Sean JD | General Secretary | Profile | |
Lourie Zak | Chief Officer | Profile | |
Joseph Cappello | Chief Officer | Profile | |
Yong Yu | Senior Development | Profile |
Additional Tools for Genelux Stock Analysis
When running Genelux Common's price analysis, check to measure Genelux Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genelux Common is operating at the current time. Most of Genelux Common's value examination focuses on studying past and present price action to predict the probability of Genelux Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genelux Common's price. Additionally, you may evaluate how the addition of Genelux Common to your portfolios can decrease your overall portfolio volatility.